82 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
for adult PK deficiency and is under investigation for pediatric PK deficiency, thalassemia, and sickle cell disease. Source: Agios internal estimates … TPP MR, April 2020. PYRUKYND® is under investigation for thalassemia and is not approved anywhere for that use.
Thalassemia in all forms remains
DEFM14A
hvbb5jhiz 2cibopqi
11 Feb 21
Proxy related to merger
4:19pm
PREM14A
nq2qqyzj
29 Jan 21
Preliminary proxy related to merger
4:22pm
DEFA14A
EX-2.1
b7nuchi3xf8ufor
21 Dec 20
Additional proxy soliciting materials
9:17pm